For personal use only

Market Announcement

9 October 2026

Identifai Genetics Limited (ASX: ID1) – Admission and Quotation

Description

Identifai Genetics Limited ('ID1') was admitted to the Official List of ASX on Friday, 9 October 2026.

The securities of ID1 will commence quotation at 12:00PM AEDT on Tuesday, 13 October 2026.

ID1 raised $10,000,000 pursuant to the offer under its prospectus dated 2 September 2026 by the issue of 50,000,000 shares at an issue price of $0.20 per share.

Quotation information

Quoted securities	Fully paid ordinary shares: 108,936,320
ASX code	Fully paid ordinary shares: ID1
Time	12:00PM AEDT
Date	Tuesday, 13 October 2026
ASX trade abbreviation	IDENTIFAI
ISIN	Fully paid ordinary shares: AU0000488983
Registered office	Address: Suite 1, 295 Rokeby Road, Subiaco WA 6008 Phone: 08 6555 2950 Email: seb@sccperth.com.au
Company secretary	Mr Sebastian Andre
Share Registry	XCEND Pty Ltd Address: PO Box R1905 Royal Exchange, NSW 1225 Phone: 02 8591 8509 Email: support@xcend.co
Balance date	31 December
CHESS	Participating. CHESS and Issuer Sponsored.
Place of incorporation	Western Australia, Australia
Dividend policy	See section 4.21 of the Prospectus
Activities	The development, validation and commercial deployment of Windrose™, a genome-wide non-invasive prenatal screening platform
Lead manager	Aesir Corporate Pty Limited
Underwriter	N/A
ASX restricted securities	79,991,766 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 13 October 2028, being 24 months from the date of official quotation.

For personal use only

	1,100,017 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 12 May 2027, being 12 months from the date of issue. 808,356 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 9 July 2027, being 12 months from the date of issue. 769,677 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 31 March 2027, being 12 months from the date of issue. 372,887 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 15 July 2027, being 12 months from the date of issue. 886,584 options exercisable at US$0.06 (A$0.08) on or before 9 December 2035, classified by ASX as restricted securities and to be held in escrow until 13 October 2028, being 24 months from the date of official quotation. 10,154,970 options exercisable at A$0.25 on or before 6 April 2029, classified by ASX as restricted securities and to be held in escrow until 13 October 2028, being 24 months from the date of official quotation. 1,518,581 options exercisable at A$0.25 on or before 28 February 2029, classified by ASX as restricted securities and to be held in escrow until 31 August 2027, being 12 months from the date of issue. 9,680,304 performance rights with a nil exercise price expiring on 31 December 2027 classified by ASX as restricted securities and to be held in escrow until 13 October 2028, being 24 months from the date of official quotation. 9,680,302 performance rights with a nil exercise price expiring on 31 December 2029 classified by ASX as restricted securities and to be held in escrow until 13 October 2028, being 24 months from the date of official quotation. 3,203,981 performance rights with a nil exercise price expiring on 31 December 2027, classified by ASX as restricted securities and to be held in escrow until 6 October 2027, being 12 months from the date of issue. 3,203,973 performance rights with a nil exercise price expiring on 31 December 2029, classified by ASX as restricted securities and to be held in escrow until 6 October 2027, being 12 months from the date of issue.
Other securities not quoted	2,498,950 options exercisable at US$0.06 (A$0.08) on or before 9 December 2035 3,559,374 options exercisable at US$0.06 (A$0.08) on or before 16 June 2034 1,774,037 options exercisable at US$0.06 (A$0.08) on or before 31 May 2033 282,490 options exercisable at US$0.06 (A$0.08) on or before 27 April 2035 434,600 options exercisable at US$0.06 (A$0.08) on or before 8 August 2033

What do I need to do and by when?

For further information, please refer to ID1's Prospectus.

For personal use only

Need more information?

For further information, please contact the Company Secretary by phone on 08 6555 2950 or by email at seb@sccperth.com.au.

Disclaimer

Please refer to the following disclaimer.

Issued by

ASX Supervision